An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis (IMAGINE-RA)
Does an MRI-guided Treatment Strategy Reduce Disease Activity and Progression in Patients With Rheumatoid Arthritis (RA): a Randomised Controlled Trial
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Patients typically experience pain, functional impairment and reduced quality of life, and are at risk of developing progressive joint damage. The disease primarily affects the small joints of the hands and feet. The current treatment strategy involves early and intensive treatment with close clinical follow up, which attempts to control the disease and avoid inflammation and thereby prevent pain, improve functional level and avoid joint damage. It is therefore important for optimal treatment of RA patients that methods used for diagnosis, disease monitoring and prognostication are highly sensitive. Erosive joint damage occurs early in the disease. Joint deformity is irreversible and causes serious functional impairment. Early and intensive treatment with close monitoring of the inflammation can slow the destructive disease and prevent function loss. However, it has been demonstrated that patients who are shown by conventional clinical and biochemical examination to have low disease activity or to be in remission can still have progressive joint damage. This demonstrates that current clinical/biochemical methods used in daily clinical practice are not sufficiently sensitive and other methods are required for the monitoring of disease activity and prognostication.
The presence of erosions (shown by X-ray examination) as well as anti-cyclic citrullinated peptide (anti-CCP) antibodies and bone marrow oedema (osteitis) on magnetic resonance imaging (MRI), are all independent predictors of subsequent radiographic progression. Bone marrow oedema has been shown to be the strongest independent predictor in early RA and MRI therefore has significant prognostic value.
It is therefore possible that supplementing conventional clinical and biochemical examinations of RA patients with MRI, and intensifying treatment where bone marrow oedema is present, will help reduce disease activity, avoid progressive joint damage and prevent function loss.
The current study is therefore based on the following hypothesis:
By supplementing conventional clinical and biochemical examination of RA patients with low disease activity/in remission with MRI and intensifying treatment in the case of sub-clinical inflammation as measured by the presence of bone marrow oedema, it is possible to prevent radiographic erosive progression, improve functional level and enable more patients to achieve clinical remission.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Aarhus, Dánia, 8600
- Dep. of Rheumatology Aarhus Hospital
-
Copenhagen, Dánia, 2000
- Dep. of Rheumatology Frederiksberg Hospital
-
Copenhagen, Dánia, 2600
- Dep. of Rheumatology Glostrup Hospital
-
Copenhagen, Dánia, 2900
- Dep. of Rheumatology Gentofte Hospital
-
Graasten, Dánia, 6300
- Dep. of Rheumatology King Christian X´Hospital for Rheumatic Diseases
-
Hjørring, Dánia, DK-9800
- Department of Rheumatology University Hospital Vendsyssel
-
Odense, Dánia, 5000
- Dep. of rheumatology Odense Hospital
-
Silkeborg, Dánia, 8600
- Dep. of Rheumatology Silkeborg Hospital
-
Slagelse, Dánia, 4200
- Dep. of Rheumatology Slagelse Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Age > 18 years
- RA according to ACR (American College of Rheumatology)/EULAR (European League Against Rheumatism) 2010 criteria.
- Anti-CCP positivity
- Erosions on conventional X-ray of hands, wrists and/or feet
- No clinically swollen joints
- DAS28 (4 variable, CRP) < 3.2
- DMARD monotherapy treatment OR combination treatment, in the form of 2- or 3-drug therapy. If the patient is undergoing 3-drug therapy, at least one of the preparations must be administered at less than the "maximum inclusion dose"*
- Unchanged anti-rheumatic treatment in the previous 6 weeks or more
- No previous treatment with biological medication
- No contra-indications for TNF-alpha-inhibiting treatment
- No contra-indications for MRI
- s-creatinine within normal range
Ability and willingness to give written and oral informed consent and fulfil the requirements of the study programme with reference to the protocol
- Maximum "inclusion dose" is defined as: MTX 25 mg/week (or maximum tolerated dose if 25 mg/week is not tolerated), SSZ 2g/day (or maximum tolerated dose if 2 g/day is not tolerated) and HCQ 200 mg/day (or maximum tolerated dose if 200 mg/day is not tolerated)
Exclusion Criteria:
- Previous or current biological treatment
- Known intolerance to methotrexate treatment which means that the patient is not able to tolerate a minimum of MTX 7.5 mg (minimum dose).
- DMARD 3-drug therapy at maximum tolerated/maximum "inclusion dose"*
- I.m, intra-articular or i.v glucocorticoid administration ≤ 6 weeks prior to inclusion
- Oral glucocorticoid administration > 5 mg/day
- Changes in oral glucocorticoid dose < 3 months prior to inclusion
- Myocrisin treatment
- Affected liver enzymes > 2 x the upper limit of normal at the time of screening
- Current and/or imminent wish to become pregnant
- Contra-indications for TNF-alpha-inhibiting treatment
- Contra-indications for MRI
- Known alcohol/drug abuse
- Inability to give informed consent
- Inability to cooperate with the study programme due to physical or mental reasons
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Aktív összehasonlító: Conventional biochemical and clinical examinations
Biochemical and clinical examinations
|
Treatment algorithm based on conventional biochemical and clinical examinations.
Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one clinically swollen joint and DAS28>3.2
|
|
Kísérleti: Conventional biochemical and clinical examinations and MRI.
Biochemical and clinical examinations and MRI.
|
Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side.
Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of "unsatisfactory inflammatory activity", which is defined as the presence of at least one physically swollen joint and DAS28>3.2
AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Időkeret |
|---|---|
|
DAS28 remission (<2.6)
Időkeret: 24 month
|
24 month
|
|
No radiographic progression (assessed by the Sharp/vdHeijde method).
Időkeret: 24 month
|
24 month
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
No radiographic progression (Sharp/vdHeijde score).
Időkeret: 24 month
|
No radiographic progression (Sharp/vdHeijde score) from 0-12 and 12-24 months and change in Sharp/vdHeijde score from 0-12, 0-24 and 12-24 months.
|
24 month
|
|
No MRI erosion (RAMRIS) score
Időkeret: 24 month
|
No progression in MRI erosion (RAMRIS) score from 0-12 and 12-24 months and change in MRI erosion (RAMRIS) score from 0-12, 0-24 and 12-24 months.
|
24 month
|
|
MRI synovitis (RAMRIS) score
Időkeret: 24 months
|
MRI synovitis (RAMRIS) score at 12 and 24 months
|
24 months
|
|
MRI bone marrow oedema (RAMRIS) score
Időkeret: 24 months
|
MRI bone marrow oedema (RAMRIS) score at 12 and 24 months
|
24 months
|
|
HAQ score
Időkeret: 24 month
|
Changes in HAQ score from 0-12 and 0-24 months
|
24 month
|
|
SF-36 score
Időkeret: 24 month
|
Changes in SF-36 score from 0-12 and 0-24 months
|
24 month
|
|
EQ-5D score
Időkeret: 24 month
|
Changes in EQ-5D score from 0-12 and 0-24 months
|
24 month
|
|
ACR/EULAR 2011 remission
Időkeret: 24 month
|
ACR/EULAR 2011 remission at 12 and 24 months
|
24 month
|
|
DAS28
Időkeret: 24 month
|
DAS28 at 12 and 24 month
|
24 month
|
|
DAS28 remission (<2.6) at 12 months
Időkeret: 24 months
|
24 months
|
|
|
biomarker analyses
Időkeret: 24 month
|
24 month
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Dynamic MRI
Időkeret: 24 month
|
Dynamic MRI variable (including initial rate of enhancement (IRE) and maximum enhancement (ME)).
|
24 month
|
Együttműködők és nyomozók
Együttműködők
Nyomozók
- Kutatásvezető: Kim Hørslev-Petersen, Professor, King Christian X´Hospital for Rheumatic Diseases
- Tanulmányi igazgató: Signe Møller-Bisgaard, MD, Dep. of Rheumatology, Rigshospitalet, Glostrup
- Tanulmányi szék: Mikkel Østergaard, Professor, Dep. of Rheumatology, Rigshospitalet, Glostrup
- Tanulmányi szék: Bo Ejbjerg, MD, PhD, Dep. of Rheumatology Slagelse Hospital
- Tanulmányi szék: Merete Hetland, MD, PhD, DMSci, Dep. of Rheumatology, Rigshospitalet, Glostrup
Publikációk és hasznos linkek
Általános kiadványok
- Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg B, Hetland ML, Christensen R, Ornbjerg LM, Glinatsi D, Moller JM, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Larsen L, Jurik AG, Thomsen HS, Ostergaard M. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial. Scand J Rheumatol. 2022 Jul;51(4):268-278. doi: 10.1080/03009742.2021.1935312. Epub 2021 Sep 2.
- Moller-Bisgaard S, Georgiadis S, Horslev-Petersen K, Ejbjerg B, Hetland ML, Ornbjerg LM, Glinatsi D, Moller J, Boesen M, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Ostergaard M. Predictors of joint damage progression and stringent remission in patients with established rheumatoid arthritis in clinical remission. Rheumatology (Oxford). 2021 Jan 5;60(1):380-391. doi: 10.1093/rheumatology/keaa496.
- Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg B, Hetland ML, Ornbjerg LM, Glinatsi D, Moller J, Boesen M, Christensen R, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Nielsen SM, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Ostergaard M. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial. JAMA. 2019 Feb 5;321(5):461-472. doi: 10.1001/jama.2018.21362.
- Moller-Bisgaard S, Horslev-Petersen K, Ejbjerg BJ, Boesen M, Hetland ML, Christensen R, Moller J, Krogh NS, Stengaard-Pedersen K, Ostergaard M. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial. Trials. 2015 Apr 21;16:178. doi: 10.1186/s13063-015-0693-2.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- IMAGINE-RA
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .